Update shared on27 Aug 2025
Fair value Decreased 3.45%The reduction in ICU Medical’s price target reflects weaker growth expectations, as consensus revenue projections have turned negative, while a lower future P/E ratio suggests diminished earnings optimism; accordingly, the fair value estimate has decreased from $182.80 to $176.50.
What's in the News
- ICU Medical raised its 2025 GAAP net loss guidance, now expecting a loss between $43 million and $35 million, with GAAP diluted loss per share between $1.68 and $1.38.
- ICU Medical was added to multiple Russell growth indexes, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, Small Cap Comp Growth, and 2000 Growth-Defensive indexes.
Valuation Changes
Summary of Valuation Changes for ICU Medical
- The Consensus Analyst Price Target has fallen slightly from $182.80 to $176.50.
- The Consensus Revenue Growth forecasts for ICU Medical has significantly fallen from 0.3% per annum to -0.1% per annum.
- The Future P/E for ICU Medical has significantly fallen from 60.36x to 53.14x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.